Netherlands promises India to stop generics seizures; Penwest Pharma in generics deal with Alvogen;

  @FiercePharma:Falling Novartis stock deflates bid for Alcon shares. Article | Follow @FiercePharma

> The Netherlands has assured India that the incidents of generic drugs seizures in Europe would not recur once the European Commission amends its regulations. Report

> Penwest Pharmaceuticals says it entered into an agreement with privately held generic manufacturer Alvogen to select up to five compounds for development. Report

> Louisiana will receive $20 million in a settlement with Indianapolis-based pharmaceutical maker Eli Lilly over claims of improper marketing of the anti-psychotic drug Zyprexa, the state attorney general has said. Report

> Cephalon says it has completed its previously announced $615 million acquisition of Mepha, the Swiss-based pharmaceutical company. Report

> China Pharmaceutical Group expects finished drugs to account for 70 percent of turnover in three to five years, a more than doubling from current levels, its chairman said on Friday. Report

> A former Novo Nordisk employee has been sentenced to one year in jail for insider trading. Report

Biotech News

   @FierceBiotech: Researchers see cancer vaccine revolution on the horizon. Story | Follow @FierceBiotech

   @JohnCFierce: Wow. Panel trashes Daxas. I'd put chances of official approval at somewhere between zip and no way. Article | Follow @JohnCFierce

> Cell Therapeutics gets widely-anticipated FDA rejection. Report

> Neovacs lowers IPO expectations. Report

> Celgene touts pipeline, stem cell drug at R&D day. Report

> Tengion IPO bring in $30 million. Report

> Sanofi opens R&D center in China. Report

And Finally... The FDA has said it is conducting a safety review of triclosan, a common ingredient in antibacterial soap. Report

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.